Journal article icon

Journal article

Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia.

Abstract:

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) suppress normal hematopoietic activity in part by enabling a pathogenic inflammatory milieu in the bone marrow. In this report, we show that elevation of angiopoietin-1 in myelodysplastic CD34+ stem-like cells is associated with higher risk disease and reduced overall survival in MDS and AML patients. Increased angiopoietin-1 expression was associated with a transcriptomic signature similar to known MDS/AML stem-like cell profil...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1158/0008-5472.CAN-15-3062

Authors


Bachegowda, L More by this author
Morrone, K More by this author
Winski, SL More by this author
Mantzaris, I More by this author
Bartenstein, M More by this author
Expand authors...
Publisher:
American Association for Cancer Research Publisher's website
Journal:
Cancer Research Journal website
Volume:
76
Issue:
16
Pages:
4841-4849
Publication date:
2016-06-05
Acceptance date:
2016-05-20
DOI:
EISSN:
1538-7445
ISSN:
0008-5472
URN:
uuid:987e7263-ed3f-42b9-bc30-2123ff7c0edb
Source identifiers:
628058
Local pid:
pubs:628058
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP